BRINGHEN, Sara
 Distribuzione geografica
Continente #
NA - Nord America 5.589
EU - Europa 3.621
AS - Asia 2.202
SA - Sud America 185
OC - Oceania 114
AF - Africa 59
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.771
Nazione #
US - Stati Uniti d'America 5.344
IT - Italia 1.187
CN - Cina 868
JP - Giappone 544
SE - Svezia 369
FR - Francia 321
GB - Regno Unito 266
IE - Irlanda 264
DE - Germania 236
IN - India 210
CA - Canada 189
ES - Italia 186
SG - Singapore 160
NL - Olanda 114
AU - Australia 103
FI - Finlandia 95
VN - Vietnam 95
AT - Austria 88
UA - Ucraina 88
KR - Corea 83
BR - Brasile 73
CH - Svizzera 68
PL - Polonia 64
HK - Hong Kong 52
TR - Turchia 46
BE - Belgio 44
GR - Grecia 41
MX - Messico 41
PT - Portogallo 37
CO - Colombia 33
HU - Ungheria 28
TW - Taiwan 26
RU - Federazione Russa 24
IL - Israele 23
PE - Perù 23
DK - Danimarca 20
AR - Argentina 19
NO - Norvegia 16
SN - Senegal 15
TH - Thailandia 14
CL - Cile 13
UY - Uruguay 12
MY - Malesia 11
RO - Romania 11
TN - Tunisia 11
CZ - Repubblica Ceca 10
HR - Croazia 10
MA - Marocco 10
NZ - Nuova Zelanda 10
PK - Pakistan 10
KW - Kuwait 9
MK - Macedonia 9
NG - Nigeria 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
ID - Indonesia 6
TT - Trinidad e Tobago 6
BO - Bolivia 5
QA - Qatar 5
AM - Armenia 4
EC - Ecuador 4
EG - Egitto 4
IR - Iran 4
MT - Malta 4
PH - Filippine 4
UZ - Uzbekistan 4
AD - Andorra 3
BG - Bulgaria 3
CU - Cuba 3
DZ - Algeria 3
EE - Estonia 3
JO - Giordania 3
KE - Kenya 3
SI - Slovenia 3
BD - Bangladesh 2
IQ - Iraq 2
KY - Cayman, isole 2
LU - Lussemburgo 2
MD - Moldavia 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
ZA - Sudafrica 2
CI - Costa d'Avorio 1
CR - Costa Rica 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
GL - Groenlandia 1
IS - Islanda 1
JM - Giamaica 1
NP - Nepal 1
PA - Panama 1
PF - Polinesia Francese 1
PY - Paraguay 1
TJ - Tagikistan 1
Totale 11.771
Città #
Fairfield 384
Chandler 330
Redwood City 263
Beijing 260
Dublin 251
Torino 236
Ashburn 231
Florence 212
Cambridge 186
Houston 167
Tokyo 167
Woodbridge 154
Wilmington 135
Ann Arbor 127
Nyköping 127
Seattle 123
Turin 116
Singapore 97
Dearborn 84
Vienna 79
Ottawa 77
Medford 74
Princeton 72
Shanghai 65
New York 64
Duncan 60
Pisa 60
Villeurbanne 59
Los Angeles 58
London 51
Dong Ket 47
Hangzhou 46
Portland 43
Madrid 42
Paris 41
Boston 40
Guangzhou 40
Rochester 39
Jacksonville 38
Nanjing 37
Raritan 35
San Diego 35
Toronto 35
Milan 34
Warsaw 34
Chicago 31
Minneapolis 30
Indianapolis 29
Norwalk 29
Seoul 29
Baltimore 28
Hyderabad 28
Perth 27
Providence 27
Rome 27
Newbury Park 26
Helsinki 25
Sydney 24
Brussels 23
Philadelphia 23
Amsterdam 22
Boardman 22
Chengdu 22
Barcelona 21
San Mateo 21
Athens 20
Osaka 20
Hebei 19
Hong Kong 19
Lima 19
St Louis 19
Brzeg 18
Pittsburgh 18
São Paulo 18
Breda 17
Budapest 17
Flushing 17
San Francisco 17
Wuhan 17
Atlanta 16
Durham 16
Xian 16
Changchun 15
Charlotte 15
Fukuoka 15
Phoenix 15
Salt Lake City 15
Toledo 15
Campi Bisenzio 14
Columbus 14
Bengaluru 13
Changsha 13
Jinan 13
Melbourne 13
Miami 13
Mumbai 13
Santiago de Cali 13
Scarsdale 13
Chennai 12
Grand Rapids 12
Totale 6.018
Nome #
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 2.496
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 1.066
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 778
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 554
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 390
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 371
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 319
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 287
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications 266
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials 262
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 252
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 238
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 226
Determining treatment intensity in elderly patients with multiple myeloma 214
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma 201
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 187
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 184
How is patient care for multiple myeloma advancing? 173
Treatment of newly diagnosed elderly multiple myeloma 166
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis 144
Emerging drugs and combinations to treat multiple myeloma 141
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups 139
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 134
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 134
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 133
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report 130
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) 115
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 114
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 113
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 100
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma 100
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma 98
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies 92
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials 90
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network 90
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. 89
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials 88
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score 84
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 81
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients 78
Treatment of newly diagnosed elderly multiple myeloma 74
Monoclonal antibodies to treat multiple myeloma: A dream come true 72
Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis 71
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. 69
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 60
Systemic virotherapy for multiple myeloma 58
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 55
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma 54
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 53
Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center 53
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction 52
Melphalan and its role in the management of patients with multiple myeloma 51
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma 51
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. 49
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy 48
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. 47
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial 47
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant 47
Approach to the Older Adult With Multiple Myeloma 45
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study 43
New treatment strategies for elderly myeloma patients 43
The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma 42
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma 39
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study 5
Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians 4
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience 4
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review 3
Totale 12.156
Categoria #
all - tutte 24.421
article - articoli 0
book - libri 0
conference - conferenze 548
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.969


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.169 49 30 44 137 89 124 116 100 205 100 97 78
2020/20212.283 74 134 164 147 206 221 195 202 232 198 202 308
2021/20222.442 174 173 149 240 176 139 269 141 127 201 300 353
2022/20232.550 151 208 184 207 178 337 183 232 256 172 246 196
2023/20242.245 176 240 161 240 191 213 169 214 60 185 200 196
2024/202586 86 0 0 0 0 0 0 0 0 0 0 0
Totale 12.156